Screener
Rigel Pharmaceuticals RIGL Single reportable segment — Outside clinical trial related expenses
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Rigel Pharmaceuticals in its filing.
Tagged under the XBRL concept rigl:OutsideClinicalTrialRelatedExpenses.
The source filing: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:05 PM EDT
- Fiscal quarter
- Q4 FY2026
- Calendar quarter
- Q4 2026
- Accession
- 0001034842-26-000032
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Less: | ||
| Employee related expenses | 21,002 | 19,538 |
| Commercial related expenses | 7,040 | 5,339 |
| Outside clinical trial related expenses | 6,927 | 4,371 |
| Cost of product sales | 4,606 | 4,409 |
| Consultants and third-party services | 4,006 | 3,409 |
| Other segment items | 3,352 | 3,494 |
| Interest expense, net | 228 | 1,262 |
Item 1. Financial Statements
FAQ
- What is Rigel Pharmaceuticals's single reportable segment — outside clinical trial related expenses?
- Rigel Pharmaceuticals (RIGL) reported single reportable segment — outside clinical trial related expenses of $6.93M in Q1 2026.
- What does single reportable segment — outside clinical trial related expenses mean?
- Reflects the costs associated with outsourced clinical research, trial management, and external medical studies. These expenses are critical for evaluating the company's R&D pipeline progression and the intensity of its clinical development efforts.
Ask your AI about Rigel Pharmaceuticals's single reportable segment — outside clinical trial related expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude